Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560499 | 0.95 | LPAR1 (0.46) | LPAR1LPAR2ENPP2KDM4EEPHX2 | |
| SCHEMBL22626935 | 0.92 | LPAR1 (0.48) | LPAR1LPAR2ENPP2EPHX2SMN1; SMN2 | |
| SCHEMBL23253802 | 0.86 | GLP1R (0.52) | GLP1RKDM4EEPHX2SMN1; SMN2SLC6A5 | |
| SCHEMBL18552064 | 0.86 | GLP1R (0.52) | GLP1RKDM4EEPHX2SMN1; SMN2SLC6A5 | |
| SCHEMBL18560334 | 0.85 | GLP1R (0.62) | GLP1REPHX2SLC6A5 | |
| SCHEMBL23567387 | 0.84 | LPAR1 (0.51) | LPAR1LPAR2ENPP2EPHX2SLC6A5 | |
| SCHEMBL18081551 | 0.84 | CNR1 (0.48) | LPAR1LPAR2ENPP2SMN1; SMN2 | |
| SCHEMBL21565261 | 0.84 | GLP1R (0.54) | GLP1RLPAR1LPAR2ENPP2KDM4E | |
| SCHEMBL24227200 | 0.84 | EPHX2 (0.48) | GLP1RKDM4EEPHX2SLC6A5 | |
| SCHEMBL23452883 | 0.83 | SMN1; SMN2 (0.45) | GLP1RKDM4EEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758426-B1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2019-08-07 | — | — | EP | disclosed |
| US-20170190757-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190757-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885LPAR1 1778/4885LPAR2 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.